FIELD: chemistry of peptides, medicine, neurology, pharmacy. SUBSTANCE: invention describes a new peptide or its salt that is able to neutralize or modulate the formation of antibodies raised to against myelin basic protein. Peptide has formula (I): R1- -Val-His-Phe-Phe-Lys-Asn-Ile-R2 where R1 is taken among the group including: Asn-Pro-Val-; Pro-Val-; Val-; Lys-Ser-His- -Gly-Arg-Thr-Gln-Asp-Glu-Asn-Pro-Val-; Thr-Gln-Asp-Glu-Asn-Pro- -Val-; hydrogen atom and hydroxy-group; R2 is taken among the group including: -Val; -Val-Thr-; -Val-Thr-Pro; -Val-Thr-Pro- -Arg-; hydrogen atom and hydroxy-group under condition that R1 and R2 are not hydrogen atom or hydroxyl simultaneously. This peptide has substitutions, additions or deletions. Invention describes also pharmaceutical composition based on compounds of the general formula (I) and method of treatment of patients with cerebrospinal sclerosis. EFFECT: enhanced effectiveness of treatment of patients. 8 cl, 10 dwg, 2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PEPTIDE FRAGMENTS OF BASIC PROTEIN MYELIN, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND APPLICATION OF THESE COMPOSITIONS FOR TREATMENT OF CEREBROSPINAL SCLEROSIS | 1998 |
|
RU2198893C2 |
PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF PATIENTS WITH CEREBROSPINAL SCLEROSIS | 1992 |
|
RU2121850C1 |
GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
PREOPERATIVE RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSION | 2019 |
|
RU2793635C2 |
DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
INTERFERON PRODRUG FOR CANCER TREATMENT | 2018 |
|
RU2788736C2 |
METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
Authors
Dates
2000-10-20—Published
1995-10-20—Filed